“Soon we will have monoclonal antibodies available that can be administered subcutaneously or intramuscularly, and in this case we must think that in many cases it will be possible to intervene at the patient’s home, without having to hospitalize him and clog the emergency rooms or medical areas of hospitals “. Like this Giorgio Palù, president ofAifa, during the hearing in the Senate Constitutional Affairs Commission, on the Ddl conversion of decree-law number 172 on vaccination obligations and strengthening of Covid-19 green certifications. These second generation antibodies “will always be administered within 72 hours of the onset of the disease”, recalled Palù, also underlining the types of monoclonal antibodies currently already available.
Palù also made it known that “for two anti-Covid antivirals, Merck’s molnupiravir (MSD outside the US and Canada) and Pfizer’s Paxlovid,“ we have received the dossier. The FDA has authorized them and the EMA is evaluating them. The intention would be to stock up, but it will be important to study the dossier. For one of the two drugs, the efficacy of the manufacturer has slightly decreased compared to the beginning “.
Support ilfattoquotidiano.it: never as in this moment do we need you
In these difficult and extraordinary times, it is essential to guarantee quality information. For us at ilfattoquotidiano.it the only masters are the readers. Unlike others, we want to offer journalism that is open to all, without paywalls. Your contribution is essential to enable us to do this. Become a supporter too
Thanks,
Peter Gomez
Support now
Previous article
Tickets for public transport only with the Green Pass, opening Minister Giovannini: “Dialogue with companies, perhaps soon the experiments”
